Context Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Context Therapeutics
CNTX Stock  USD 1.52  0.02  1.33%   
Context Therapeutics financial statements provide useful quarterly and yearly information to potential Context Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Context Therapeutics financial statements helps investors assess Context Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Context Therapeutics' valuation are summarized below:
Market Capitalization
114 M
Earnings Share
(0.88)
We have found one hundred fourteen available fundamental signals for Context Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Context Therapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 17.1 M in 2024. Enterprise Value is likely to drop to about 3.4 M in 2024
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Context Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets22.7 M16.1 M24.4 M
Very volatile
Other Current Liabilities1.1 M1.8 M546.7 K
Slightly volatile
Total Current Liabilities6.2 M4.2 M7.6 M
Pretty Stable
Other Liabilities24.8 K26.1 K1.1 M
Slightly volatile
Accounts Payable1.6 M2.4 M1.8 M
Pretty Stable
Cash20.2 M14.4 M19.7 M
Pretty Stable
Long Term Debt59 K62.1 K972.7 K
Slightly volatile
Good Will1.1 M1.3 M1.4 M
Slightly volatile
Other Current Assets1.4 M1.6 M1 M
Slightly volatile
Total Liabilities8.3 M4.2 M11.3 M
Pretty Stable
Deferred Long Term Liabilities100.6 K105.9 K3 M
Slightly volatile
Short and Long Term Debt8.5 M6.8 M6 M
Slightly volatile
Preferred Stock Total Equity130.1 M175.8 M120.6 M
Slightly volatile
Total Current Assets28.9 M16 M21 M
Pretty Stable
Short Term Debt120.3 K126.7 K4.2 M
Very volatile
Intangible Assets5.5 M6.2 M6.8 M
Slightly volatile
Common Stock10.1 K18.4 K8.4 K
Slightly volatile
Property Plant Equipment35.6 K26.1 K43.7 K
Slightly volatile
Short and Long Term Debt Total47.1 K49.6 K15 M
Slightly volatile
Non Current Assets Total14.7 K15.5 K43.3 K
Pretty Stable
Cash And Short Term Investments22 M14.4 M8.3 M
Slightly volatile
Common Stock Total Equity35.7537.9532.8467
Slightly volatile
Common Stock Shares Outstanding15.4 M18.4 M12.4 M
Slightly volatile
Liabilities And Stockholders Equity23.3 M16.1 M8.8 M
Slightly volatile
Capital Stock10.7 K18.4 K4.3 K
Slightly volatile

Context Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative9.1 M7.3 M19.4 M
Slightly volatile
Research Development8.9 M17.8 M17.1 M
Slightly volatile
Total Operating Expenses12.9 M25.1 M22 M
Slightly volatile
Other Operating Expenses26.3 M25.1 M8.7 M
Slightly volatile
Interest Income997.9 K1.3 M625.3 K
Slightly volatile
Selling And Marketing Expenses9.6 K10.8 K11.8 K
Slightly volatile

Context Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings127.4 K134.1 K15.1 M
Slightly volatile
End Period Cash Flow18.6 M14.4 M8.5 M
Slightly volatile
Stock Based Compensation783 K1.1 M754.6 K
Very volatile
Begin Period Cash Flow19.1 M35.5 M7.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.8 M2 M2.2 M
Slightly volatile
Capex To Depreciation46.3452.1356.7651
Slightly volatile
Payables Turnover0.00820.00510.0095
Slightly volatile
Cash Per Share1.010.9050.499
Slightly volatile
Days Payables Outstanding43.6 K72.2 K39.7 K
Slightly volatile
Net Debt To EBITDA0.550.57664.0069
Slightly volatile
Current Ratio5.213.82832.5248
Slightly volatile
Graham Number4.425.01095.6152
Slightly volatile
Capex Per Share0.01970.03030.0181
Slightly volatile
Interest Debt Per Share0.04120.04341.4443
Slightly volatile
Debt To Assets0.00160.001754.0833
Slightly volatile
Days Of Payables Outstanding43.6 K72.2 K39.7 K
Slightly volatile
Quick Ratio5.213.82832.5248
Slightly volatile
Net Income Per E B T1.051.111.0846
Slightly volatile
Cash Ratio4.943.44722.3964
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.941.0094
Slightly volatile
Debt Ratio0.00160.001754.0833
Slightly volatile

Context Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap17.1 M18 M46.9 M
Slightly volatile

Context Fundamental Market Drivers

Cash And Short Term Investments14.4 M

Context Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue12 K12.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY